China Import Medical Device Testing Requirements: 5 Key Regulatory Changes Foreign Manufacturers Must Know in 2025

In a major regulatory update effective February 1, 2025, China’s 国家药品监督管理局 (National Medical Products Administration, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú) introduced five key changes to import medical device testing requirements that affect all 60,000+ registered medical devices currently on the Chinese market. The new rules mandate on-site factory testing for 30% of Class II and III imported devices, reduce NMPA review timelines from 180 to 153 days for priority devices, and require 78 updated testing standards aligned with international norms — a move that could add RMB 500,000 to RMB 2,000,000 in compliance costs per device application.

1. Mandatory On-Site Factory Testing for Class II and III Imported Devices

The most significant change under the new NMPA circular is the expansion of mandatory on-site testing requirements. Previously, the NMPA accepted testing reports from NMPA-recognized overseas laboratories for most imported devices. Under the 2025 rules, 30% of Class II and Class III imported devices will require physical on-site testing at NMPA-designated testing centers in China — specifically Beijing, Shanghai, and Guangzhou. This represents a sharp increase from the 8% of devices that required on-site testing under the 2021 rules.

The affected device categories include active implantable devices (Class III), high-frequency surgical equipment, and imaging diagnostics systems. Foreign manufacturers must now factor in an additional 8 to 12 weeks for sample shipping, customs clearance, and in-country testing. The NMPA has stated that on-site testing costs will range from RMB 120,000 to RMB 450,000 per device type, depending on complexity.

2. Updated Quality Management System (QMS) Documentation Requirements

The second major change concerns QMS documentation. The NMPA now requires imported device manufacturers to submit 质量管理体系文件 (Quality Management System documentation, zhìliàng guǎnlǐ tǐxì wénjiàn) that complies with the updated GB/T 42061-2024 standard, which aligns with ISO 13485:2016 but includes five China-specific clauses. These clauses cover traceability requirements for distributors, post-market surveillance reporting in Chinese, and recall plan templates that must be pre-approved by provincial NMPA offices.

The new documentation rules apply to all new device registrations submitted after February 1, 2025. For existing registrations undergoing renewal from 2026 onward, manufacturers must submit updated QMS documentation at least 180 days before expiry. Industry estimates suggest that updating QMS documentation to comply with GB/T 42061-2024 will cost foreign manufacturers between RMB 80,000 and RMB 200,000 per device family, including translation and legal review.

3. Streamlined NMPA Review Process — But with Higher Technical Standards

The NMPA has simultaneously streamlined its review process while raising technical barriers. Under the 2025 changes, the NMPA review timeline for priority imported devices — those on the “Innovation Medical Device” list or serving unmet clinical needs — has been reduced from 180 working days to 153 working days, a 15% improvement. However, the number of required technical documents has increased from 12 to 18, with three entirely new requirements: (1) a cybersecurity risk assessment report for connected devices, (2) a biocompatibility evaluation per GB/T 16886 series updates, and (3) a real-world clinical data analysis from the device’s home market.

This trade-off means that while the administrative timeline has shortened, the technical preparation phase for foreign manufacturers has lengthened by an estimated 10 to 14 weeks. The NMPA reported in its Q4 2024 review that 42% of submitted import device applications were rejected on first review due to incomplete or non-compliant testing documentation — up from 31% in 2023.

4. Clinical Evaluation Pathway Changes — More Data Now Required

The fourth key change affects clinical evaluation pathways for imported devices. The NMPA now requires clinical data from the Chinese population for all Class III imported devices unless the manufacturer can demonstrate equivalence to a device already marketed in China for at least five years without significant adverse events. For Class II devices, the NMPA accepts clinical data from the device’s home country market but requires a minimum of 200 patient cases — a threshold that was previously 100 cases.

This change has significant implications for rare-device categories and first-in-class technologies entering China. The NMPA has indicated that it will accept multi-country clinical data pooled from up to three markets (e.g., EU, US, and Japan) to meet the Chinese population data requirement, but the data must be analyzed separately for Chinese patients if the device has been used in China through clinical trials. The clinical evaluation report itself must now follow the updated 医疗器械临床评价指南 (Medical Device Clinical Evaluation Guidelines, yīliáo qìxiè línchuáng píngjià zhǐnán) released in December 2024.

5. New Testing Standards Alignment — 78 Standards Updated Since Q3 2024

Finally, the NMPA has published 78 updated testing standards since Q3 2024, with 34 of them taking effect on February 1, 2025, and the remaining 44 phased in through December 2025. These standards cover electromagnetic compatibility (EMC), electrical safety, and biological evaluation. Notably, the new EMC standard (GB 4824-2024) imposes stricter emission limits for medical electrical equipment operating in industrial, scientific, and medical (ISM) frequency bands — a change that affects 15–20% of imported diagnostic imaging devices currently on the market.

Foreign manufacturers must test all devices against these updated standards before submitting new registration applications. For devices already registered, the NMPA has granted a 12-month transition period — until February 1, 2026 — for compliance. However, any design changes made during this period must immediately comply with the new standards, which may accelerate replacement cycles for older device models.

Comparative Table: Old vs. New Testing Requirements for Imported Medical Devices

Three Critical Pitfalls for Foreign Manufacturers

NEXT STEPS

1. Audit your current device portfolio against the 2025 requirements. Use our Medical Device Testing Compliance Checklist to identify which of your devices fall under the new on-site testing mandate and which standards updates apply to each product.
2. Engage an NMPA-registered testing laboratory now. Testing slots at NMPA-designated centers in Beijing, Shanghai, and Guangzhou are filling up rapidly. Contact our Testing Center Booking Service to reserve a slot within the next 6–8 weeks.
3. Review your clinical data strategy for Class III devices. Schedule a consultation with our regulatory team to assess whether your existing clinical data meets the new Chinese population requirements, or whether you need a bridging study. Book a Regulatory Strategy Consultation to evaluate your options.

— China Gateway 360 —
Remote China market entry support, built around execution.